Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Sanofi Winthrop Industrie

< Previous 1 2 3 4 Next >
News headline image
Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi launches 2026 global employee stock purchase plan
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi successfully prices 2.3 billion of bond issue
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Q1 2026: double-digit sales and business EPS growth
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press release: Availability of the Q1 2026 aide-mémoire
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release:  Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease
From Sanofi Winthrop Industrie
Via GlobeNewswire
News headline image
Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
From Sanofi Winthrop Industrie
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.